Olema Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sean Bohen
- Full Time Employees
- 150
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 780 Brannan Street San Francisco CA United States of America 94103
- IPO Date
- Nov 19, 2020
- CIK
- 0001750284
- Website
- olema.com
- Similar Companies
- Business
- Olema Pharmaceuticals Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company headquartered in San Francisco, California and founded in 2006, discovers, develops and seeks to commercialize targeted therapies for women's cancers, with a primary focus on endocrine-driven breast cancer; its lead product candidate, palazestrant (OP-1250), comprises a proprietary, orally available complete estrogen receptor (ER) antagonist and selective ER degrader (CERAN/SERD) evaluated in multiple Phase 3 OPERA trials for ER+/HER2- metastatic breast cancer, including monotherapy in second- and third-line settings versus fulvestrant or aromatase inhibitors, first-line combination with Novartis' ribociclib (Kisqali), second-line combinations with CDK4/6 inhibitors such as palbociclib and ribociclib, and additional combinations with Pfizer's atirmociclib (CDK4 inhibitor), Roche's alpelisib (PI3K inhibitor for PIK3CA-mutated tumors), and everolimus (mTOR inhibitor); the company additionally advances OP-3136, an orally available small molecule KAT6 inhibitor in Phase 1 for ER+/HER2- metastatic breast cancer, castrate-resistant prostate cancer, and lung cancer. Olema Pharmaceuticals maintains global commercial and marketing rights to palazestrant, with all clinical data and inventions from key trials jointly owned with partners; it targets patients with significant unmet needs in ER+ breast cancer and expands into other solid tumors leveraging expertise in nuclear receptors and resistance mechanisms. Recent developments include a December 2024 clinical trial collaboration and supply agreement with Novartis enabling the pivotal Phase 3 OPERA-02 trial initiation in mid-2025 for palazestrant plus ribociclib in frontline ER+/HER2- metastatic breast cancer, accompanied by a $250 million equity private placement from investors including Adage Capital Partners LP, Bain Capital Life Sciences and Wellington Management; a September 2025 clinical trial agreement with Pfizer to assess palazestrant with atirmociclib in a Phase 1/2 study informing potential frontline pivotal development; and a November 2025 $218.5 million public offering of common stock with full underwriters' option exercise, bolstering resources for OPERA-01, OPERA-02, and OP-3136 advancement.
Company News
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)